BUZZ-斯普鲁斯生物科学股价大涨,因其推进罕见儿童脑部疾病药物的FDA申请

路透中文
Feb 18
BUZZ-斯普鲁斯生物科学股价大涨,因其推进罕见儿童脑部疾病药物的FDA申请

2月18日 - ** 药物开发商Spruce Biosciences SPRB.O的股价盘前上涨27%至74美元

** 该公司称其疗法针对的是桑菲利波综合征B型,这是一种罕见的遗传性疾病,会导致儿童进行性脑损伤和运动能力丧失。

** 该公司称,FDA确认其现有临床数据可以支持对其实验性酶替代疗法进行加速审查

** 公司称,该疗法旨在替代缺失的酶,以减缓或阻止疾病进展

** 公司称,该药物已在22名患者中进行了为期六年的测试,安全性良好

** SPRB 表示,在完成 FDA 的生产要求后,预计将于 2026 年第四季度提交申请。

** 2025 年股价上涨约 177%

(为便利非英文母语者,路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误,或未能包含所需语境,路透不保证自动化翻译文本的准确性,仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失,路透不承担任何责任。)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10